NEW YORK (TheStreet) -- Provectus Biopharmaceuticals (PVCT) plunged Wednesday after the site amended its website homepage to call PV-10 an "investigational drug for cancer" after it had previously called it a "breakthrough cancer drug."
TheStreet's Adam Feuerstein posted an article with screenshots of the two homepage descriptions and he points out Provectus is supposed to get a response from the FDA this week about its request to grant PV-10 Breakthrough Therapy status for skin cancer. The company has said nothing thus far about the FDA's response.
Seeking Alphaalso posted an extremely bearish article on Provectus on Wednesday.
The stock was down 18.15% to $2.21 at 12:08 p.m.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.